These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 18217197)

  • 41. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients.
    Efthimiou P; Schwartzman S; Kagen LJ
    Ann Rheum Dis; 2006 Sep; 65(9):1233-6. PubMed ID: 16476710
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Successful treatment of refractory rash in paraneoplastic amyopathic dermatomyositis.
    Aslanidis S; Pyrpasopoulou A; Kartali N; Zamboulis C
    Clin Rheumatol; 2007 Jul; 26(7):1198-200. PubMed ID: 16779504
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical efficacy of intravenous immunoglobulin for patients with MPO-ANCA-associated rapidly progressive glomerulonephritis.
    Ito-Ihara T; Ono T; Nogaki F; Suyama K; Tanaka M; Yonemoto S; Fukatsu A; Kita T; Suzuki K; Muso E
    Nephron Clin Pract; 2006; 102(1):c35-42. PubMed ID: 16174989
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of childhood dermatomyositis with high dose intravenous immunoglobulin.
    Vedanarayanan V; Subramony SH; Ray LI; Evans OB
    Pediatr Neurol; 1995 Nov; 13(4):336-9. PubMed ID: 8771171
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Can we face the challenge of expanding use of intravenous immunoglobulin in neurology?
    Elovaara I; Hietaharju A
    Acta Neurol Scand; 2010 Nov; 122(5):309-15. PubMed ID: 20085560
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intravenous immunoglobulin treatment for pregnancy-associated dermatomyositis.
    Linardaki G; Cherouvim E; Goni G; Boki KA
    Rheumatol Int; 2011 Jan; 31(1):113-5. PubMed ID: 19844719
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Critical review of the role of intravenous immunoglobulins in idiopathic inflammatory myopathies.
    Anh-Tu Hoa S; Hudson M
    Semin Arthritis Rheum; 2017 Feb; 46(4):488-508. PubMed ID: 27908534
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy.
    Hahn AF; Beydoun SR; Lawson V; ; Oh M; Empson VG; Leibl H; Ngo LY; Gelmont D; Koski CL
    J Peripher Nerv Syst; 2013 Dec; 18(4):321-30. PubMed ID: 24725024
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of high-dose immune globulin intravenous in the treatment of dermatomyositis.
    Dalakas MC
    Int Immunopharmacol; 2006 Apr; 6(4):550-6. PubMed ID: 16504918
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An intravenous immunoglobulin therapy of serious autoimmune rheumatic diseases.
    Lukan N; Lazurova I; Racz O; Kristofova B; Tkac I
    Bratisl Lek Listy; 2008; 109(11):489-92. PubMed ID: 19205557
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China.
    Yang Y; Xu J; Li F; Zhu X
    Int J Dermatol; 2009 Oct; 48(10):1122-8. PubMed ID: 19775409
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Experimental study on the use of intravenous immunoglobulin (IVIg) in patients with steroid-resistant Crohn's disease.
    Chrissafidou A; Malek M; Musch E
    Z Gastroenterol; 2007 Jul; 45(7):605-8. PubMed ID: 17620224
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis.
    Raja J; Nihtyanova SI; Murray CD; Denton CP; Ong VH
    Rheumatology (Oxford); 2016 Jan; 55(1):115-9. PubMed ID: 26320139
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose intravenous immunoglobulin for oral corticosteroid-dependent asthma.
    Kishiyama JL; Valacer D; Cunningham-Rundles C; Sperber K; Richmond GW; Abramson S; Glovsky M; Stiehm R; Stocks J; Rosenberg L; Shames RS; Corn B; Shearer WT; Bacot B; DiMaio M; Tonetta S; Adelman DC
    Clin Immunol; 1999 May; 91(2):126-33. PubMed ID: 10227804
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Steroid sparing effect of intravenous immunoglobulin therapy in patients with pemphigus foliaceus.
    Sami N; Qureshi A; Ahmed AR
    Eur J Dermatol; 2002; 12(2):174-8. PubMed ID: 11872417
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [TREATMENT OF REFRACTORY RHINOSINUSITIS IN PATIENTS WITH IGE-DEFICIENCY].
    Tsaryk VV
    Lik Sprava; 2014 Dec; (12):3-10. PubMed ID: 26638461
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cyclosporin A in the treatment of refractory adult polymyositis/dermatomyositis: population based experience in 6 patients and literature review.
    Qushmaq KA; Chalmers A; Esdaile JM
    J Rheumatol; 2000 Dec; 27(12):2855-9. PubMed ID: 11128676
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety of intravenous immunoglobulin in the elderly treated for a dysimmune neuromuscular disease.
    Lozeron P; Not A; Theaudin M; Denier C; Masnou P; Sarov M; Adam C; Cauquil C; Adams D
    Muscle Nerve; 2016 May; 53(5):683-9. PubMed ID: 26467654
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intravenous immunoglobulin therapy for neuromuscular disorders.
    Ross MA
    Semin Neurol; 2007 Sep; 27(4):340-6. PubMed ID: 17701871
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population.
    Unger L; Kampf S; Lüthke K; Aringer M
    Rheumatology (Oxford); 2014 Sep; 53(9):1630-8. PubMed ID: 24706995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.